Annexin Pharmaceuticals AB (publ)

DB:Q91 Stock Report

Market Cap: €26.5m

Annexin Pharmaceuticals Future Growth

Future criteria checks 2/6

Annexin Pharmaceuticals is forecast to grow earnings and revenue by 4.2% and 213.8% per annum respectively.

Key information

4.2%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth rate213.8%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:Q91 - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202552-14N/AN/A1
12/31/2024N/A-61N/AN/A1
6/30/2024N/A-52-52-52N/A
3/31/2024N/A-46-45-45N/A
12/31/2023N/A-44-43-43N/A
9/30/2023N/A-40-43-43N/A
6/30/2023N/A-38-40-40N/A
3/31/2023N/A-41-43-43N/A
12/31/2022N/A-41-41-41N/A
9/30/2022N/A-47-39-39N/A
6/30/2022N/A-45-39-39N/A
3/31/2022N/A-43-40-40N/A
12/31/2021N/A-52-45-45N/A
9/30/2021N/A-53-47-47N/A
6/30/2021N/A-53-48-48N/A
3/31/2021N/A-55-48-48N/A
12/31/2020N/A-44-39-39N/A
9/30/2020N/A-38-34-34N/A
6/30/2020N/A-36-30-30N/A
3/31/2020N/A-31-24-24N/A
12/31/2019N/A-28-26-26N/A
9/30/2019N/A-25-24-24N/A
6/30/2019N/A-24-26-26N/A
3/31/2019N/A-25-27-27N/A
12/31/2018N/A-29-29-29N/A
9/30/2018N/A-31-33-33N/A
6/30/2018N/A-30-36-35N/A
3/31/2018N/A-32N/A-39N/A
12/31/2017N/A-31N/A-39N/A
9/30/2017N/A-25N/A-36N/A
6/30/2017N/A-26N/A-29N/A
3/31/2017N/A-17N/A-18N/A
12/31/2016N/A-10N/A-10N/A
12/31/2015N/A-5N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Q91 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: Q91 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: Q91 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Q91's revenue (213.8% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: Q91's revenue (213.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if Q91's Return on Equity is forecast to be high in 3 years time


Discover growth companies